BTLA and neoplasm: Preclinical studies of tifcemalimab (anti-BTLA antibody) and toripalimab (anti-PD-1 antibody) also showed that BTLA blockade works synergistically along with PD-1 blockade to restore T cell function in reporter cells with high BTLA and PD-1 expression and to enhance anti-tumor effect in mouse models.